Clinuvel Pharmaceuticals Ltd (CLVLF)
CLVLF is quoted over the counter, not listed on an exchange. Clinuvel Pharmaceuticals Ltd files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | CLVLF, quoted over the counter |
| SEC CIK | 0001290877 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | American Depositary Receipts |
| Business address | Melbourne, Victoria |
| Incorporated in | Australia |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-10-30 |
| Cash and burn | $13.9M cash; operating cash flow $3.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 50,427,898 (2026-06-30). | Cover page 2026-06-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton Audit Pty Ltd, Melbourne, Australia | PCAOB Form AP 2026-07-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | $64.3M | $23.2M | $12.9M | $13.9M | No debt tags | $64.3M | 20-F 2026-10-30 |
| FY 2025 2025-06-30 | $61.1M | $23.1M | $27.3M | $18.1M | No debt tags | $61.1M | 20-F 2026-10-30 |
| FY 2024 2024-06-30 | $57.9M | $23.3M | $23.8M | Not filed | No debt tags | $57.9M | 20-F 2026-10-30 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-07-17 |
| Latest annual report | 20-F | 2026-10-30 |
| Latest quarterly / interim | 6-K | 2026-10-30 |
Source: SEC EDGAR submissions feed, 49 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier